Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corp (Nasdaq: LUNG) delivers innovative minimally invasive solutions for severe lung diseases, including its FDA-cleared Zephyr Valve system. This news hub provides essential updates for stakeholders tracking medical advancements and corporate developments in interventional pulmonology.
Access real-time updates on clinical trial milestones, regulatory approvals, and strategic partnerships that shape treatment paradigms for emphysema and COPD. Our curated collection features earnings reports, product launch details, and peer-reviewed research findings - all vital for understanding Pulmonx's market position.
Key content includes analysis of pulmonary treatment innovations, global commercialization efforts, and financial performance metrics. Investors and healthcare professionals will find timely information on FDA submissions, international expansion, and clinical outcome studies that demonstrate improved patient quality of life.
Bookmark this page for centralized access to Pulmonx's latest advancements in bronchoscopic lung volume reduction technology. Stay informed about developments that impact both respiratory care standards and long-term corporate growth strategies.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025.
The company will host a conference call with management to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the earnings call through the investor relations section of Pulmonx's website.
Pulmonx (NASDAQ: LUNG) reported strong financial results for Q4 and full year 2024. The company achieved record worldwide revenue of $83.8 million for FY2024, up 22% year-over-year, and Q4 2024 revenue of $23.8 million, a 23% increase from Q4 2023.
U.S. revenue reached $56.5 million for FY2024 (23% growth) and $15.9 million for Q4 2024 (16% growth). The company maintained a gross margin of 74% throughout 2024. Net loss for FY2024 improved to $56.4 million ($1.44 per share) compared to $60.8 million ($1.60 per share) in 2023.
For 2025, Pulmonx projects revenue between $96-98 million (15-17% growth) and expects to maintain a 74% gross margin. Operating expenses are forecasted at $133-135 million, including $22 million in stock-based compensation.
Pulmonx (Nasdaq: LUNG), a pioneer in minimally invasive treatments for severe lung disease, has announced its participation in an upcoming investor event. The company will engage in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on February 27, 2025, at 8:00 AM PT / 11:00 AM ET.
Interested parties can access both live and archived versions of the presentation through the 'Investors' section of the Pulmonx website at investors.pulmonx.com.
Pulmonx (NASDAQ: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. The company will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the event through the company's investor relations website.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will engage in a fireside chat on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET in New York. Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website.
Pulmonx (Nasdaq: LUNG) and the American Lung Association are expanding their partnership with two new educational initiatives for severe COPD and emphysema patients. The programs include patient stories on the EACH BREATH blog in November 2024 featuring experiences with endobronchial valve (EBV) treatment, and an 'Ask the Expert' Q&A session with a pulmonologist in January on the Lung Association's online communities. The collaboration aims to increase awareness about Zephyr® Endobronchial Valve therapy and provide educational resources for patients and healthcare providers dealing with COPD, which remains the third leading cause of death worldwide according to WHO.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The company will engage in investor meetings at the event, which is scheduled to take place in New York on Thursday, November 21, 2024.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET in New York.
Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/.
Pulmonx (LUNG) reported Q3 2024 financial results with worldwide revenue of $20.4 million, up 15% year-over-year. U.S. revenue grew 17% to $13.8 million, while international revenue increased 12% to $6.6 million. The company maintained a gross margin of 74% and reported a net loss of $14.1 million ($0.36 per share). Operating expenses increased 3% to $29.2 million. The company added 15 new Zephyr Valve treatment centers and maintains its full-year 2024 revenue guidance of $81-84 million with expected gross margin of 74%.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced that it will release its third quarter 2024 financial results after the close of trading on Wednesday, October 30, 2024. The company management will host a conference call to discuss the financial results, starting at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Investors and interested parties can access a live and archived webcast of the event on the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
